Senhwa Biosciences Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jin-Ding Huang
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 3yrs |
CEO ownership | n/a |
Management average tenure | 1.9yrs |
Board average tenure | 7.6yrs |
CEO
Jin-Ding Huang
3yrs
Tenure
Dr. Jin-Ding Huang, PhD, serves as Chief Executive Officer at Senhwa Biosciences, Inc. since 2022 and serves as its President and served as its General Manager until January 01, 2025 and served as its Dire...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive VP | 10.8yrs | NT$8.76m | no data | |
President & CEO | 3yrs | no data | no data | |
Acting Chief Operating Officer & Business Development Director | 1.9yrs | no data | no data | |
Director of Regulatory & Legal Affairs | less than a year | no data | no data | |
Chief Medical Officer | less than a year | no data | no data |
1.9yrs
Average Tenure
Experienced Management: 6492's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman | 12.2yrs | no data | 2.04% NT$ 79.0m | |
Supervisor | 9.8yrs | no data | no data | |
Director | 2yrs | no data | no data | |
Supervisor | 8.6yrs | no data | no data | |
Director | 7.6yrs | no data | no data | |
Independent Director | 9.8yrs | NT$160.00k | no data | |
Supervisor | 7.6yrs | no data | no data | |
Independent Director | 4.6yrs | NT$80.00k | no data | |
Independent Director | 4.6yrs | NT$80.00k | no data | |
Director | less than a year | no data | no data |
7.6yrs
Average Tenure
Experienced Board: 6492's board of directors are considered experienced (7.6 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/11 21:09 |
End of Day Share Price | 2025/01/10 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Senhwa Biosciences, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Yenya Kuo | Capital Securities Corporation |
Jane Jiang | Yuanta Research |